Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cerecor Inc (AVTX)
Cerecor Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Avalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVTX : 0.0836 (-1.42%)
IONS : 49.41 (+2.21%)
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review

The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.

PCRX : 27.02 (-1.75%)
RCEL : 10.66 (-1.02%)
AVTX : 0.0836 (-1.42%)
EQRX : 2.34 (-2.09%)
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal

Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.

NVO : 102.00 (+0.56%)
RCEL : 10.66 (-1.02%)
AVTX : 0.0836 (-1.42%)
EQRX : 2.34 (-2.09%)
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device

Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.

RHHBY : 33.8100 (+0.74%)
NVO : 102.00 (+0.56%)
LLY : 591.86 (+0.04%)
AVTX : 0.0836 (-1.42%)
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate....

ALT : 3.13 (+0.64%)
RCEL : 10.66 (-1.02%)
AVTX : 0.0836 (-1.42%)
EQRX : 2.34 (-2.09%)
ACER's Stock Down on Failure of Phase II Study, Cash Updates

ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

SNY : 46.60 (-0.81%)
ACER : 0.6601 (-17.95%)
AZYO : 1.4900 (+2.05%)
AVTX : 0.0836 (-1.42%)
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote

FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.

PFE : 30.08 (+1.31%)
NVO : 102.00 (+0.56%)
MRK : 101.13 (+0.95%)
AVTX : 0.0836 (-1.42%)
Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

CPRX : 14.05 (-1.13%)
RCEL : 10.66 (-1.02%)
AZYO : 1.4900 (+2.05%)
AVTX : 0.0836 (-1.42%)
Origin Materials and Avantium to Accelerate the Mass Production of FDCA and PEF for Advanced Chemicals and Plastics

Origin Materials, Inc. (“Origin” and “Origin Materials”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable...

ORGN : 0.7700 (-2.53%)
ORGNW : 0.0416 (-16.63%)
AVTX : 0.0836 (-1.42%)
Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates

Verve Therapeutics (VERV) delivered earnings and revenue surprises of -5.33% and 81.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VERV : 11.20 (-6.12%)
AVTX : 0.0836 (-1.42%)

Barchart Exclusives

1 Top Crypto Stock to Buy for Bitcoin Exposure
MicroStrategy is effectively a Bitcoin holding company, and its share price is tied to the performance of Bitcoin. Should you buy MSTR stock at the current valuation? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar